Previous research conducted by our group on various tumor types has indicated that specific genetic profiles, such as KIR alone or KIR–HLA combinations, can serve as predictors for responses to cetuximab and trastuzumab [17,18]. This evidence concerns the gene KIR3DL1 and neoplasm.